Arthritis drug Vimovo’s slow sales are a pain to Pozen
If you only looked at Pozen‘s (NASDAQ:POZN) top and bottom lines from its third-quarter earnings, you might have missed a key detail affecting the pharmaceutical company’s financial performance. Although Chapel Hill, North Carolina-based Pozen’s revenue grew and its loss narrowed in the third quarter, the company insists results should be better and management pins those […]